CL2020000966A1 - Tratamiento de enfermedad mediada por smc - Google Patents

Tratamiento de enfermedad mediada por smc

Info

Publication number
CL2020000966A1
CL2020000966A1 CL2020000966A CL2020000966A CL2020000966A1 CL 2020000966 A1 CL2020000966 A1 CL 2020000966A1 CL 2020000966 A CL2020000966 A CL 2020000966A CL 2020000966 A CL2020000966 A CL 2020000966A CL 2020000966 A1 CL2020000966 A1 CL 2020000966A1
Authority
CL
Chile
Prior art keywords
smc
treatment
mediated disease
prophylaxis
dysfunction
Prior art date
Application number
CL2020000966A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Wei Wen Lim
Benjamin Wei Ming Ng
Original Assignee
Singapore Health Serv Pte Ltd
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd, Nat Univ Singapore filed Critical Singapore Health Serv Pte Ltd
Publication of CL2020000966A1 publication Critical patent/CL2020000966A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Diagnóstico, tratamiento y profilaxis de enfermedades y afecciones asociadas con disfunción de las células del músculo liso (SMC) que se proporcionan a través de la inhibición de la señalización mediada por IL-11.
CL2020000966A 2017-10-12 2020-04-09 Tratamiento de enfermedad mediada por smc CL2020000966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1716733.9A GB201716733D0 (en) 2017-10-12 2017-10-12 Treatment of SMC mediated disease

Publications (1)

Publication Number Publication Date
CL2020000966A1 true CL2020000966A1 (es) 2021-02-26

Family

ID=60419332

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000966A CL2020000966A1 (es) 2017-10-12 2020-04-09 Tratamiento de enfermedad mediada por smc

Country Status (14)

Country Link
US (2) US11780898B2 (es)
EP (1) EP3694876A1 (es)
JP (2) JP7704526B2 (es)
KR (1) KR102801430B1 (es)
CN (1) CN111655724A (es)
AU (1) AU2018347676B2 (es)
BR (1) BR112020007139A2 (es)
CA (1) CA3077368A1 (es)
CL (1) CL2020000966A1 (es)
EA (1) EA202090691A1 (es)
GB (1) GB201716733D0 (es)
MX (1) MX2020003668A (es)
PH (1) PH12020550255A1 (es)
WO (1) WO2019073057A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
US20200397816A1 (en) * 2019-06-24 2020-12-24 The Trustees Of Indiana University Methods to treat inflammatory and smooth muscle cell proliferation disorders
MX2023009946A (es) * 2021-02-26 2023-09-04 Bayer Ag Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN116983413A (zh) * 2023-08-04 2023-11-03 中国医学科学院阜外医院 Plekhh2在肺动脉高压诊断和治疗方面的应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
US8361966B2 (en) 2006-10-27 2013-01-29 Osaka University Use of interleukin-11 as therapeutic agent for heart disease
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CN104995211B (zh) 2013-02-07 2019-09-13 Csl有限公司 Il-11r结合蛋白及其应用
WO2017049349A1 (en) * 2015-09-25 2017-03-30 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment and prophylaxis
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
AU2017378111A1 (en) * 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
EP3399398B1 (en) * 2017-05-02 2022-04-13 Nokia Technologies Oy An apparatus and associated methods for presentation of spatial audio
AU2018262790B2 (en) * 2017-05-05 2023-12-21 Huvepharma Functionalized saccharides as anti-inflammatory agents
GB201809699D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
US20240141004A1 (en) 2024-05-02
JP7704526B2 (ja) 2025-07-08
MX2020003668A (es) 2020-08-20
AU2018347676A1 (en) 2020-05-21
WO2019073057A1 (en) 2019-04-18
CA3077368A1 (en) 2019-04-18
EA202090691A1 (ru) 2020-12-07
US20190241637A1 (en) 2019-08-08
PH12020550255A1 (en) 2020-12-07
JP7704806B2 (ja) 2025-07-08
KR102801430B1 (ko) 2025-04-25
AU2018347676B2 (en) 2025-03-06
EP3694876A1 (en) 2020-08-19
CN111655724A (zh) 2020-09-11
KR20200093533A (ko) 2020-08-05
BR112020007139A2 (pt) 2020-10-20
JP2020536921A (ja) 2020-12-17
JP2023113725A (ja) 2023-08-16
US11780898B2 (en) 2023-10-10
GB201716733D0 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
CL2020000966A1 (es) Tratamiento de enfermedad mediada por smc
CL2021001228A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CR20210592A (es) Moduladores de la vía integrada del estrés
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
MX382216B (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CL2017002223A1 (es) Métodos para el tratamiento de trastornos del movimiento involuntario anormal
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
CL2017002781A1 (es) Métodos de tratamiento de enfermedad de alzheimer
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
UY38338A (es) INHIBIDORES DE LA INTERACCIÓN PROTEÍNA-PROTEÍNA KEAP1-Nrf2
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
AR106133A1 (es) Métodos para el tratamiento de la epilepsia